Kinase News and Research

RSS

New pathway for inflammation-induced cancer

A well-known inflammatory protein spawns an enzyme that inactivates two tumor-suppressing genes, ultimately triggering production of new blood vessels to nourish breast cancer cells, researchers at The University of Texas M. D. Anderson Cancer Center report in the August edition of the journal Cell .

11 Aug 2007

Sex and gender in cardiovascular-renal physiology and pathophysiology

Gender influences the prevalence and progression rate of many renal diseases, such as polycystic kidney disease (PKD).

9 Aug 2007

New way to predict how cells will respond to targeted drug therapies

Models based on this approach could help doctors make better treatment choices for individual patients, who often respond differently to the same drug, and could help drug developers identify the ideal compounds on which to focus their research.

1 Aug 2007

Chromosomes responsible for a critical enzyme's activation during cell division

In a dividing cell, chromosomes interact with cellular scaffolding - called spindle microtubules - in order to move themselves to opposite ends of the cell, ensuring that both daughter cells receive an exact copy of their parent cell's genetic material.

1 Aug 2007

Scientists clarify molecular basis of interferon action

Scientists at the University of California, Santa Barbara have made a significant discovery relating to viral infections in humans.

20 Jul 2007

Protein kinase G holds promise for cancer treatment

An enzyme that cancer cells eliminate, apparently so they can keep proliferating, may hold clues to more targeted, effective cancer treatment, scientists say.

19 Jul 2007

Heart patches that stimulate regeneration

When human hearts are injured, as during a heart attack, healthy tissue normally can't regrow.

18 Jul 2007

Discovery of molecular mechanism behind fear

Researchers from MIT's Picower Institute for Learning and Memory have uncovered a molecular mechanism that governs the formation of fears stemming from traumatic events.

16 Jul 2007

New advance in search for effective treatment for human liver cancer

Researchers from the University of Pittsburgh School of Medicine report a significant new advance in the search for an effective treatment for human liver cancer in the July issue of Molecular Cancer Therapeutics.

12 Jul 2007

Cancer-causing enzyme could be stopped

Scientists from the MRC's Laboratory of Molecular Biology (LMB) and the Albert Einstein College of Medicine have discovered a way to stop an enzyme responsible for many cancers.

11 Jul 2007

Adiponectin serves as energy-conserving signal to the brain

A fat-derived protein known for its effects on the liver and skeletal muscle might also serve as an energy-conserving signal to the brain during periods of starvation, suggests a new study in the July issue of Cell Metabolism, a publication of Cell Press.

11 Jul 2007

Trastuzumab and chemo improves survival in women with operable HER-2 positive breast cancer

A recent meta-analysis of five major breast cancer trials has confirmed that combination treatment with the antibody trastuzumab and chemotherapy improves survival in women with operable HER-2 positive breast cancer.

9 Jul 2007

Genetic mutation that may alter response to cancer therapeutics found

Researchers from Eli Lilly & Company and the Phoenix-based Translational Genomics Research Institute (TGen) today announced finding a novel recurring mutation of the gene AKT1 in breast, colorectal and ovarian cancers.

4 Jul 2007

New model for signal transduction in cells

Among the key communication systems within a cell is the Wnt signaling pathway, which regulates embryonic development and whose deregulation can also contribute to cancer development.

28 Jun 2007

Bayer and Onyx submit supplemental NDA for Nexavar

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals have announced that a Supplemental New Drug Application (sNDA) for Nexavar (sorafenib) tablets has been submitted to the U.S. Food and Drug Administration (FDA) for the treatment of patients with hepatocellular carcinoma (HCC), the most common form of liver cancer. Nexavar is currently approved in more than 50 countries for the treatment of advanced kidney cancer.

28 Jun 2007